Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

The Activity of Antimicrobial Surfaces Varies by Testing Protocol Utilized.

Campos MD, Zucchi PC, Phung A, Leonard SN, Hirsch EB.

PLoS One. 2016 Aug 5;11(8):e0160728. doi: 10.1371/journal.pone.0160728. eCollection 2016.

2.

Surface microbiology of the iPad tablet computer and the potential to serve as a fomite in both inpatient practice settings as well as outside of the hospital environment.

Hirsch EB, Raux BR, Lancaster JW, Mann RL, Leonard SN.

PLoS One. 2014 Oct 31;9(10):e111250. doi: 10.1371/journal.pone.0111250. eCollection 2014.

3.

Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.

Dilworth TJ, Leonard SN, Vilay AM, Mercier RC.

Clin Ther. 2014 Oct 1;36(10):1334-44. doi: 10.1016/j.clinthera.2014.06.027. Epub 2014 Jul 25.

PMID:
25066667
4.

Activated ClpP kills persisters and eradicates a chronic biofilm infection.

Conlon BP, Nakayasu ES, Fleck LE, LaFleur MD, Isabella VM, Coleman K, Leonard SN, Smith RD, Adkins JN, Lewis K.

Nature. 2013 Nov 21;503(7476):365-70. doi: 10.1038/nature12790. Epub 2013 Nov 13.

5.

Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection.

Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, LaPlante KL, Potoski BA, Rybak MJ.

Antimicrob Agents Chemother. 2013 Sep;57(9):4252-4259. doi: 10.1128/AAC.00380-13. Epub 2013 Jun 24.

6.

Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus.

Leonard SN, Supple ME, Gandhi RG, Patel MD.

Antimicrob Agents Chemother. 2013 Jun;57(6):2678-83. doi: 10.1128/AAC.02127-12. Epub 2013 Apr 1.

7.

Evaluation of the combination of daptomycin and nafcillin against vancomycin-intermediate Staphylococcus aureus.

Leonard SN, Rolek KM.

J Antimicrob Chemother. 2013 Mar;68(3):644-7. doi: 10.1093/jac/dks453. Epub 2012 Nov 14.

PMID:
23152482
8.

An introductory review module for an anti-infectives therapeutics course.

Leonard SN, Murphy K, Zaeem M, DiVall MV.

Am J Pharm Educ. 2012 Sep 10;76(7):135. doi: 10.5688/ajpe767135.

9.

Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.

Leonard SN.

PLoS One. 2012;7(7):e42103. doi: 10.1371/journal.pone.0042103. Epub 2012 Jul 24.

10.

Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines.

Kullar R, Leonard SN, Davis SL, Delgado G Jr, Pogue JM, Wahby KA, Falcione B, Rybak MJ.

Pharmacotherapy. 2011 May;31(5):441-8. doi: 10.1592/phco.31.5.441.

PMID:
21923425
11.

Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).

Leonard SN, Szeto YG, Zolotarev M, Grigoryan IV.

Int J Antimicrob Agents. 2011 Jun;37(6):558-61. doi: 10.1016/j.ijantimicag.2011.02.007. Epub 2011 Apr 14.

PMID:
21497067
12.

In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.

Vidaillac C, Leonard SN, Rybak MJ.

Int J Antimicrob Agents. 2010 Jun;35(6):527-30. doi: 10.1016/j.ijantimicag.2010.02.006. Epub 2010 Mar 26.

PMID:
20346632
13.

Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance.

Rong SL, Leonard SN.

Ann Pharmacother. 2010 May;44(5):844-50. doi: 10.1345/aph.1M526. Epub 2010 Mar 23. Review.

PMID:
20332341
14.

In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.

Vidaillac C, Leonard SN, Rybak MJ.

Antimicrob Agents Chemother. 2009 Nov;53(11):4712-7. doi: 10.1128/AAC.00636-09. Epub 2009 Sep 8.

15.
16.

In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.

Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ.

Antimicrob Agents Chemother. 2009 Jun;53(6):2360-6. doi: 10.1128/AAC.01452-08. Epub 2009 Apr 6.

17.

Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides.

Leonard SN, Rossi KL, Newton KL, Rybak MJ.

J Antimicrob Chemother. 2009 Mar;63(3):489-92. doi: 10.1093/jac/dkn520. Epub 2009 Jan 9.

PMID:
19136530
18.

Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model.

Rose WE, Leonard SN, Rossi KL, Kaatz GW, Rybak MJ.

Antimicrob Agents Chemother. 2009 Feb;53(2):805-7. doi: 10.1128/AAC.01009-08. Epub 2008 Nov 17.

20.

Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus.

Leonard SN, Kaatz GW, Rucker LR, Rybak MJ.

J Antimicrob Chemother. 2008 Dec;62(6):1305-10. doi: 10.1093/jac/dkn379. Epub 2008 Sep 18.

PMID:
18801920
21.

Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).

Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN.

J Clin Microbiol. 2008 Sep;46(9):2950-4. doi: 10.1128/JCM.00582-08. Epub 2008 Jul 16. Erratum in: J Clin Microbiol. 2008 Dec;46(12):4119. Sadar, Helio S [corrected to Sader, Helio S].

23.

Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.

Leonard SN, Cheung CM, Rybak MJ.

Antimicrob Agents Chemother. 2008 Aug;52(8):2974-6. doi: 10.1128/AAC.00257-08. Epub 2008 Jun 2.

25.

Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.

Leonard SN, Rybak MJ.

Pharmacotherapy. 2008 Apr;28(4):458-68. doi: 10.1592/phco.28.4.458. Review.

PMID:
18363530
26.

Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum.

Tsuji BT, Leonard SN, Rhomberg PR, Jones RN, Rybak MJ.

Diagn Microbiol Infect Dis. 2008 Apr;60(4):441-4. doi: 10.1016/j.diagmicrobio.2007.11.011. Epub 2008 Jan 14.

PMID:
18248936
27.

daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Rose WE, Leonard SN, Sakoulas G, Kaatz GW, Zervos MJ, Sheth A, Carpenter CF, Rybak MJ.

Antimicrob Agents Chemother. 2008 Mar;52(3):831-6. Epub 2007 Nov 12.

Supplemental Content

Loading ...
Support Center